The first thing you notice is the name, TIESyno-96, printed in a clean, technical font on a machine that looks like a high-end coffee maker crossed with a laboratory centrifuge. It is a desktop DNA printer. The promise, printed just as cleanly in the product literature, is that you can write genes, not just read them, from the bench where you run your PCRs. This is the physical artifact of a quiet bet being placed in a Tianjin lab: that the future of synthetic biology isn't in a centralized factory, but in a piece of equipment any researcher can own.
Zhonghe Gene, founded in 2022 by researcher Huifeng Jiang, is building that equipment. The company's flagship product, the TIESyno-96 DNA biosynthesizer, alongside related gene splicers and reagents, represents a push into enzymatic DNA synthesis [Preqin]. This so-called "third-generation" technique uses enzymes to assemble DNA strands, positioning itself as a greener, more precise alternative to the traditional chemical synthesis methods dominated by giants like Twist Bioscience. For a biologist engineering a custom protein or a team prototyping a new biomaterial, the tool isn't a service to outsource, it's a piece of lab infrastructure.
A hardware wedge into the code of life
The strategic wedge is the machine itself. By selling the synthesizer, Zhonghe Gene isn't just providing a service, it's installing a platform. The model is familiar from other tech hardware plays: anchor with the capital equipment, then build a recurring revenue stream through the proprietary consumables and reagents that keep it running. In this case, the consumables are the enzymes and nucleotides, and the recurring work is the DNA itself. The company also offers synthesis services, but the hardware is the core of its bid to move gene writing from a centralized, outsourced step to an integrated, on-demand part of the research workflow. It's a bet on democratization, with a business model attached.
Backed by the blueprint of regional ambition
The company's funding tells a distinctly regional story. While amounts are undisclosed, the investors are a map of local Chinese industrial and scientific policy. A seed round in early 2024 included Apricot Capital and Beiyang Haitang Fund [Crunchbase, Feb 2024]. A more recent venture round in January 2026 was led by the Changzhou Municipal Government Investment Fund Management, with participation from Lenovo [Preqin, Jan 2026]. This isn't purely venture capital speculation, it's strategic capital aligned with national and municipal priorities in biotech and advanced manufacturing. The backing suggests Zhonghe Gene is seen not just as a commercial startup, but as a piece of infrastructure in China's broader synthetic biology blueprint.
| Investor | Type | Round (Date) |
|---|---|---|
| Changzhou Municipal Government Investment Fund Management | Government Fund | Venture (Jan 2026) |
| Apricot Capital | Venture Capital | Seed (Feb 2024) |
| Beiyang Haitang Fund | Venture Capital | Seed (Feb 2024) |
| Lenovo | Corporate Venture | Venture (Jan 2026) |
The crowded lab bench
The field Zhonghe Gene is entering is both nascent and crowded with well-funded contenders. The shift to enzymatic synthesis has sparked a global race, with companies like Ansa Biotechnologies and DNA Script advancing their own platforms. These competitors are also chasing the same vision of benchtop synthesis, often with deeper venture backing and more public traction. Zhonghe Gene's current visibility outside of Chinese investment circles is limited, with no named customer deployments or tier-one international press yet on the record. The company's success will hinge on a few critical, unproven motions.
- Technical parity. The core assumption is that the TIESyno-96's synthesis fidelity, speed, and cost can match or beat not only traditional chemical methods but also other enzymatic platforms. Any significant lag in performance would be fatal.
- The academic beachhead. The most logical early adopters are research institutes like the Tianjin Institute of Industrial Biotechnology, where founder Huifeng Jiang is a researcher [Preqin]. Converting academic labs into reference accounts is a necessary first step, but the real scale lies in biopharma and industrial biotech.
- The global footprint. To date, the narrative and funding are intensely local. Winning in synthetic biology is an international game. The company's next chapter will require crossing that boundary, convincing global R&D departments that a Tianjin-based hardware platform belongs in their workflow.
The next twelve months
The immediate roadmap is written in the details of the January 2026 funding round. The lead investor is a municipal fund from Changzhou, a city with a stated focus on building out its life sciences cluster [Changzhou Government, Apr 2024]. This suggests the capital is for execution, not just R&D. The next year should see the transition from development to deployment, with the first commercial installations of the TIESyno-96 serving as the ultimate proof point. Key signals to watch will be any partnership announcements with domestic pharmaceutical or agritech firms, and whether the company begins to list international distributors.
The cultural question the TIESyno-96 is built to answer is one of agency. For decades, writing DNA meant sending a sequence to a faceless service provider and waiting. It was a transaction. Zhonghe Gene's machine, sitting on the lab bench, proposes a different relationship. It asks researchers if they want DNA synthesis to be a utility, like electricity, or a tool, like a pipette. The bet is that biologists, given the means, will choose the tool. They will want to iterate on the code of life with the same immediacy they bring to amplifying it.
Sources
- [Preqin, Jan 2026] Tianjin Zhonghe Gene Technology profile | https://www.preqin.com/data/profile/asset/tianjin-zhonghe-gene-technology/528288
- [Crunchbase, Feb 2024] Zhonghe Gene Seed Round | https://www.crunchbase.com/funding_round/zhonghe-gene-seed--bf4353d9
- [Changzhou Government, Apr 2024] Zhonghe Gene set to launch DNA synthesis equipment project in Changzhou | https://www.changzhou.gov.cn/ns_news/384171412044614